nach oben

Erschienen in:

01.06.2007

α1,2Fucosylation Is a Superior Predictor of Postoperative Prognosis for Colorectal Cancer Compared with Blood Group A, B, or Sialyl Lewis X Antigen Generated within Colorectal Tumor Tissues

verfasst von: Kaori Tsuboi, MD, Takayuki Asao, MD, PhD, Munenori Ide, MD, PhD, Shinji Hashimoto, MD, Kasumi Noguchi, PhD, Yoshihiko Kominato, MD, PhD, Abby R. Saniabadi, PhD, Hiroyuki Kuwano, MD, PhD, Shin Yazawa, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

We have previously demonstrated tumor-specific α1,2fucosylation, which is associated with resistance of tumor cells to anticancer treatment in human colorectal tumor tissues. By using the YB-2 monoclonal antibody, the resulting products have been identified as Y, Le^b, and H type 2 antigens in colorectal tumor tissues.

Methods

Immunohistochemical analyses of colorectal cancer tissues (74 specimens) were performed with a newly established mouse monoclonal antibody, YB-3 specifically recognizing H disaccharide (Fucα1,2Galβ) structures, and anti-A, anti-B, YB-2, and anti–sialyl Lewis X (SLX) antibodies, together with the analyses of glycosyltransferases involved in the synthesis of ABH antigens in the same tissues.

Results

The YB-3 antibody enabled us to detect colorectal tumors, particularly tumors in the distal large intestine and the rectum, with high sensitivity (74.3%) and specificity (100%). From immunohistochemical and enzymatic analyses of colorectal tissues, we found that once α1,2fucosylation had proceeded in tumor tissues, blood group A or B antigen was also synthesized in approximately half of the tissues of A or B blood type, but not in their normal tissues. A correlation of survival rate with immunostaining of tissues was found only by YB-3 antibody and not by anti-A, anti-B, or anti-SLX antibody.

Conclusions

As a predictor of postoperative prognosis of patients with colorectal cancer, immunodetection of α1,2fucosylated antigens with the YB-3 antibody seemed to be superior to blood groups A, B, or SLX antigen in colorectal tumor tissues.

Hakomori S. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta 1999;1473:247–66PubMed

Le Pendu J, Marionneau S, Cailleau-Thomas A, et al. ABH and Lewis histo-blood group antigens in cancer. APMIS 2001;109:9–31PubMedCrossRef

Varki A. Glycosylation changes in cancers. In: Varki A, Cummings R, Esko J, Freeze H, Hart G, Marth J, eds. Essentials of Glycobiology, Cold Spring Harbor NY: Cold Spring Harbor Press, 1999;537–49

Yazawa S, Nishihara S, Iwasaki H, et al. Genetic and enzymatic evidence for Lewis enzyme expression in Lewis-negative cancer patients. Cancer Res 1995;55:1473–8PubMed

Nakamura J, Mogi A, Asao T, Nagamachi Y, Yazawa S. Evidence that the aberrant αl→2fucosyltransferase found in colorectal carcinoma may be encoded by Fuc-TIII (Le) gene. Anticancer Res 1997;17:4563–9PubMed

Ørntoft TF, Greenwell P, Clausen H, Watkins WM. Regulation of the oncodevelopmental expression of type 1 chain ABH and Lewis(b) blood group antigens in human colon by alpha-2-L-fucosylation. Gut 1991;32:287–93PubMed

Yazawa S, Akamatsu S, Tachikawa T, et al. Development and characterization of a novel anti-fucosylated antigen monoclonal antibody YB-2 and its usefulness in the immunohistochemical diagnosis of colorectal cancer. Jpn J Cancer Res 1993;84:641–8PubMed

Akamatsu S, Yazawa S, Tachikawa T, et al. α2→3sialyltransferase associated with the synthesis of CA 19-9 in colorectal tumors. Cancer 1996;77:1694–700PubMed

Naitoh H, Nakajima T, Nagamachi Y, Yazawa S. A clinicopathological evaluation of anti-fucosylated antigens antibody (YB-2) in colorectal carcinoma. Glycosylation Dis 1994;1:31–6CrossRef

10.

Yazawa S, Nakamura J, Asao T, et al. Aberrant α1→2 fucosyltransferases found in human colorectal carcinoma involved in the accumulation of Le^b and Y antigens in colorectal tumors. Jpn J Cancer Res 1993;84:989–95PubMed

11.

Yazawa S, Nishimura T, Ide M, et al. Tumor-related expression of α 1,2fucosylated antigens on colorectal carcinoma cells and its suppression by cell-mediated priming using sugar acceptors for α1,2fucosyltransferase. Glycobiology 2002;12:545–53PubMedCrossRef

12.

Sun J, Thurin J, Cooper HS, et al. Elevated expression of H type GDP-L-fucose: β-D-galactoside α-2-L-fucosyltransferase is associated with human colon adenocarcinoma progression. Proc Natl Acad Sci U S A 1995;92:5724–8PubMedCrossRef

13.

Orlow I, Lacombe L, Pellicer I, et al. Genotype and phenotypic characterization of the histoblood groups ABO(H) in primary bladder tumors. Int J Cancer 1998;75:819–24PubMedCrossRef

14.

Iwamoto S, Withers DA, Handa K, Hakomori S. Deletion of A-antigen in a human cancer cell line is associated with reduced promoter activity of CBF/NF-Y binding region, and possibly with enhanced DNA methylation of A transferase promoter. Glycoconjugate J 1999;16:659–66CrossRef

15.

Kominato Y, Hata Y, Takizawa H, Tsuchiya T, Tsukada J, Yamamoto F. Expression of human histo-blood group ABO genes is dependent upon DNA methylation of the promoter region. J Biol Chem 1999;274:37240–50PubMedCrossRef

16.

Gao S, Worm J, Guldberd P, et al. Genetic and epigenetic alteration of the blood group ABO gene in oral squamous cell carcinoma. Int J Cancer 2004;109:230–7PubMedCrossRef

17.

Ichikawa D, Handa K, Withers DA, Hakomori S. Histo-blood group A/B versus H status of human carcinoma cells as correlated with haptotactic cell motility: approach with A and B gene transfection. Cancer Res 1997;57:3092–6PubMed

18.

Ichikawa D, Handa K, Hakomori S. Histo-blood group A/B antigen deletion/ reduction vs. continuous expression in human tumor cells as correlated with their malignancy. Int J Cancer 1998;76:284–9PubMedCrossRef

19.

Gao S, Bennett EP, Reibel J, et al. Histo-blood group ABO antigen in oral potentially malignant lesions and squamous cell carcinoma-genotypic and phenotypic characterization. APMIS 2004;112:11–20PubMedCrossRef

20.

Graziano SL, Tatum AH, Gonchoroff NJ, Newman NB, Kohman LJ. Blood group antigen A and flow cytometric analysis in resected early-stage non–small cell lung cancer. Clin Cancer Res 1997;3:87–93PubMed

21.

Yazawa S, Takeya A, Hosomi O, et al. Use of synthetic H disaccharides as acceptors for detecting activities of UDP-GalNAc:Fuc αl→2Gal β-R α1→3-N-acetylgalactosaminyltransferase in plasma samples from blood group A subgroups. Clin Chem 1992;38:2392–5PubMed

22.

Sobin LH, Wittekind C, eds. TNM: Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss, 2002

23.

Yazawa S, Madiyalakan R, Izawa H, et al. Cancer-associated elevation of α(l→3)-L-fucosyltransferase activity in human serum. Cancer 1988;62:516–520PubMedCrossRef

24.

Yazawa S, Asao T, Izawa H, et al. The presence of CA19-9 in serum and saliva from Lewis blood-group negative cancer patients. Jpn J Cancer Res 1988;79:538–43PubMed

25.

Akamatsu S, Yazawa S, Zenita K, et al. Elevation of an α(l,3)fucosyltransferase activity correlated with apoptosis in human colon adenocarcinoma cell line, HT-29. Glycoconj J 1996;13:985–93CrossRef

26.

Nishihara S, Hiraga T, Ikehara Y, et al. Molecular mechanisms of expression of Lewis b antigen and other type 1 Lewis antigens in human colorectal cancer. Glycobiology 1999;9:607–16PubMedCrossRef

27.

Fujitani N, Liu Y, Toda S, et al. Expression of H type 1 antigen of ABO histo-blood group in normal colon and aberrant expressions of H type 2 and H type 3/4 antigens in colon cancer. Glycoconjugate J 2000;17:331–8CrossRef

28.

Hakomori S. Tumor malignancy of defined by aberrant glycosylation and sphingo-(glyco)lipid metabolism. Cancer Res 1996;56:5309–18PubMed

29.

Lee JS, Ro JY, Sahin AA, et al. Expression of blood-group antigen-A—a favorable prognostic factor in non–small-cell lung cancer. N Engl J Med 1991;324:1084–90PubMedCrossRef

30.

Dabelsteen E. ABO blood group antigens in oral mucosa. What is new? J Oral Pathol Med 2002;31:65–70PubMed

31.

Marionneau S, Le Moullac-Vaidve B, Le Pendu J. Expression of histo-blood group A antigen increases resistance to apoptosis and facilitates escape from immune control of rat colon carcinoma cells. Glycobiology 2002;12:851–6PubMedCrossRef

32.

Nakagoe T, Nanashima A, Sawai T, et al. Expression of blood group antigens A, B and H in carcinoma tissue correlates with a poor prognosis for colorectal cancer patients. J Cancer Res Clin Oncol 2000;126:375–82PubMedCrossRef

33.

Nakagoe T, Fukushima K, Nanashima A, et al. Comparison of the expression of ABH/Lewis-related antigens in polypoid and non-polypoid growth types of colorectal carcinoma. J Gastroenterol Hepatol 2001;16:176–83PubMedCrossRef

34.

Sakuma Y, Kubishiro K, Tsukazaki K, Nozawa S. Involvement of H type 1 carbohydrate antigen in cell adhesion to vascular endothelial cells of human endometrial cancer. Anticancer Res 2003;23:1277–82PubMed

35.

Nakamura M, Kudo T, Narimatsu H, et al. Single glycosyltransferase, core 2 β1→6-N-actylglucosaminyltransferase, regulates cell surface sialyl-Le^x expression level in human pre-B lymphocytic leukemia cell line KM3 treated with phorbolester. J Biol Chem 1998;273:26779–89PubMedCrossRef

36.

Mathieu S, Prorol M, Benoliel A, et al. Transgene expression of α(l,2)-fucosyltransfease-I (FUT1) in tumor cells selectively inhibits sialyl-Lewis x expression and binding to E-selectin without affecting synthesis of sialyl-Lewis or binding to P-selecin. Am J Pathol 2004;164:371–83PubMed

37.

Labarrière N, Pian JP, Otry C, et al. H blood group antigen carried by CD44V modulates tumorigenicity of rat colon carcinoma cells. Cancer Res 1994;54:6275–81PubMed

38.

Goupille C, Hallouin F, Meflah K, Le Pendu J. Increase of rat colon carcinoma cells tumorigenicity by α(l-2)fucosyltransferase gene transfection. Glycobiology 1997;7:221–9PubMedCrossRef

39.

Hallouin F, Goupille C, Bureau V, Meflah K, Le Pendu J. Increased tumorigenicity of rat colon carcinoma cells after 2-fucosyltranferase FTA anti-sense cDNA transfection. Int J Cancer 1999;80:601–11CrossRef

40.

Cordel S, Goupille C, Hallouin F, et al. Role of α1,2fucosyltransferase and histo-blood group H antigen type 2 in resistance of rat colon carcinoma cells to 5-fluorouracil. Int J Cancer 2000;85:142–8PubMedCrossRef

41.

Goupille C, Marionneau S, Bureau V, et al. α1,2Fucosyltransferase increases resistance to apoptosis of rat colon carcinoma cells. Glycobiology 2000;10:375–82PubMedCrossRef

42.

Zerfaoui M, Fukuda M, Sbarra V, Lombardo D, El-Battari A. α(l,2)-Fucosylation prevents sialyl Lewis x expression and E-selectin–mediated adhesion of fucosyltransferase VII-transfected cells. Eur J Biochem 2000;267:53–60PubMedCrossRef

43.

Chihara Y, Sugano K, Kobayashi A, et al. Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene. Lab Invest 2005;85:895–907PubMedCrossRef

Titel: α1,2Fucosylation Is a Superior Predictor of Postoperative Prognosis for Colorectal Cancer Compared with Blood Group A, B, or Sialyl Lewis X Antigen Generated within Colorectal Tumor Tissues
verfasst von: Kaori Tsuboi, MD
Takayuki Asao, MD, PhD
Munenori Ide, MD, PhD
Shinji Hashimoto, MD
Kasumi Noguchi, PhD
Yoshihiko Kominato, MD, PhD
Abby R. Saniabadi, PhD
Hiroyuki Kuwano, MD, PhD
Shin Yazawa, PhD
Publikationsdatum: 01.06.2007
Verlag: Springer-Verlag
Erschienen in: Annals of Surgical Oncology / Ausgabe 6/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9363-2

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2007

Pelvic Exenteration Affords Safe and Durable Treatment for Locally Advanced Rectal Carcinoma

Regional Lymph Node Metastases; a Singular Manifestation of the Process of Clinical Metastases in Cancer: Contemporary Animal Research and Clinical Reports Suggest Unifying Concepts

Teaching Palliative Care and End-of-Life Issues: A Core Curriculum for Surgical Residents

Differential Expression and Prognostic Implications of the CCN Family Members WISP-1, WISP-2, and WISP-3 in Human Breast Cancer

Determination of the Necessary Total Protein Substitution Requirements in Patients with Advanced Stage Ovarian Cancer and Ascites, Undergoing Debulking Surgery. Correlation with Plasma Proteins

Detection of First Relapse in Cutaneous Melanoma Patients: Implications for the Formulation of Evidence-Based Follow-up Guidelines

Update Chirurgie